Over the past fifty years the somatic mutation theory of cancer has emerged as the most successful explanation of the molecular phenotype...

The essential molecular requirements for the transformation of normal cells into established cancer cells, with implications for a novel...

March 4th 2023 Hilmar Warenius’ Patent on new lead agent ONKONEK filed by SYNTHERIX June 7TH 2023 Peer reviewed new hypothesis about how...

Reaction Biology GmbH will collaborate in developiment of a specific PKM2 assay for ONKONEK activity in human cancers.

GB2582571A describing SYNTHERIX unique Coumarin / Naphthalene/ Arginine warhead is at present in PCT in Europe and the USA. A new patent...